Clinical significance of estrogen receptor phosphorylation

Endocrine-Related Cancer

Volumn 18, Issue 1, 2011, Pages

  Murphy, Leigh C ^a,b   Seekallu, Srinivas V ^a,b   Watson, Peter H ^b,c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; LETROZOLE; TAMOXIFEN;

BREAST CANCER; CANCER GROWTH; CANCER INVASION; CANCER RESISTANCE; CELLULAR DISTRIBUTION; DIMERIZATION; DNA BINDING; HUMAN; IN VIVO STUDY; LIGAND BINDING; OUTCOME ASSESSMENT; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; REVIEW; RNA SPLICING; TUMOR BIOPSY;

ANTINEOPLASTIC AGENTS, HORMONAL; BIOPSY; BREAST NEOPLASMS; CARCINOMA; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM PROTEINS; NEOPLASMS, HORMONE-DEPENDENT; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN KINASES; PROTEIN PROCESSING, POST-TRANSLATIONAL; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; TAMOXIFEN; TREATMENT OUTCOME;

EID: 79251518293     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-10-0070     Document Type: Review

References (123)

1. Acconcia F, Manavathi B, Mascarenhas J, Talukder AH, Mills G & Kumar R 2006 An inherent role of integrin-linked kinase-estrogen receptor alpha interaction in cell migration. Cancer Research 66 11030-11038. (doi:10.1158/0008-5472.CAN-06-2676)
2. Adeyinka A, Niu Y, Cherlet T, Snell L, Watson P & Murphy L 2002 Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression. Clinical Cancer Research 8 1747-1753.
3. Arnold S, Obourn J, Jaffe H & Notides A 1994 Serine 167 is the major estradiol-induced phosphorylation site on the human estrogen receptor. Molecular Endocrinology 8 1208-1214. (doi:10.1210/me.8.9.1208)
4. Arnold S, Obourn J, Jaffe H & Notides A 1995a Phosphorylation of the human estrogen receptor on tyrosine 537 in vivo and by Src family tyrosines in vitro. Molecular Endocrinology 9 24-33. (doi:10.1210/me.9.1.24)
5. Arnold S, Vorojeikina D & Notides A 1995b Phosphorylation of tyrosine 537 on the human estrogen receptor is required for binding to an estrogen response element. Journal of Biological Chemistry 270 30205-30212. (doi:10.1074/jbc.270.4.1850)
6. Arnold SF, Melamed M, Vorojeikina DP, Notides AC & Sasson S 1997 Estradiol-binding mechanism and binding capacity of the human estrogen receptor is regulated by tyrosine phosphorylation. Molecular Endocrinology 11 48-53. (doi:10.1210/me.11.1.48)
7. Assender JW, Gee JM, Lewis I, Ellis IO, Robertson JF & Nicholson RI 2007 Protein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancer. Journal of Clinical Pathology 60 1216-1221. (doi:10.1136/jcp.2006.041616)
8. Atsriku C, Britton DJ, Held JM, Schilling B, Scott GK, Gibson BW, Benz CC & Baldwin MA 2009 Systematic mapping of posttranslational modifications in human estrogen receptor-α with emphasis on novel phosphorylation sites. Molecular and Cellular Proteomics 8 467-480. (doi:10.1074/mcp.M800282-MCP200)
9. Auboeuf D, Hönig A, Berget SM & O'Malley BW 2002 Coordinate regulation of transcription and splicing by steroid receptor coregulators. Science 298 416-419. (doi:10.1126/science.1073734)
10. Auboeuf D, Batsché E, Dutertre M, Muchardt C & O'Malley BW 2007 Coregulators: transducing signal from transcription to alternative splicing. Trends in Endocrinology and Metabolism 18 122-129. (doi:10.1016/j.tem.2007.02.003)
11. Bardou V, Arpino G, Elledge R, Osborne C & Clark G 2003 Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. Journal of Clinical Oncology 21 1973-1979. (doi:10.1200/JCO.2003.09. 099)
12. Barlund M, Monni O, Kononen J, Cornelison R, Torhorst J, Sauter G, Kallioniemi O-P & Kallioniemi A 2000 Multiple genes at 17q23 undergo amplification and overexpression in breast cancer. Cancer Research 60 5340-5344.
13. Barnes RO, Parisien M, Murphy LC & Watson PH 2008 Influence of evolution in tumor biobanking on the interpretation of translational research. Cancer Epidemiology, Biomarkers and Prevention 17 3344-3350. (doi:10.1158/1055-9965.EPI-08-0622)
14. Barone I, Iacopetta D, Covington KR, Cui Y, Tsimelzon A, Beyer A, Ando S & Fuqua SA 2010 Phosphorylation of the mutant K303R estrogen receptor a at serine 305 affects aromatase inhibitor sensitivity. Oncogene 29 2404-2414. (doi:10.1038/onc.2009.520)
15. Bergqvist J, Elmberger G, Ohd J, Linderholm B, Bjohle J, Hellborg H, Nordgren H, Borg A, Skoog L & Bergh J 2006 Activated ERK1/2 and phosphorylated oestrogen receptor α are associated with improved breast cancer survival in women treated with tamoxifen. European Journal of Cancer 42 1104-1112. (doi:10.1016/j.ejca.2006.01.028)
16. Bostner J, Skoog L, Fornander T, Nordenskjold B & Stal O 2010 Estrogen receptor-α phosphorylation at serine 305, nuclear p21-activated kinase 1 expression, and response to tamoxifen in postmenopausal breast cancer. Clinical Cancer Research 16 1624-1633. (doi:10.1158/1078-0432.CCR-09-1733)
17. Britton D, Scott G, Schilling B, Atsriku C, Held J, Gibson B, Benz C & BaldwinM2008 A novel serine phosphorylation site detected in the N-terminal domain of estrogen receptor isolated from human breast cancer cells. Journal of the American Society for Mass Spectrometry 19 729-740. (doi:10.1016/j.jasms.2008.02.008)
18. Campbell R, Bhat-Nakshatri P, Patel N, Constantinidou D, Ali S & Nakshatri H 2001 Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. Journal of Biological Chemistry 276 9817-9824. (doi:10.1074/jbc.M010840200)
19. Castana E, Vorojeikina D & Notides A 1997 Phosphorylation of serine-167 on the human oestrogen receptor is important for oestrogen response element binding and transcriptional activation. Biochemical Journal 326 149-157.
20. Chen D, Pace P, Coombes R & Ali S 1999 Phosphorylation of human estrogen receptor α by protein kinase A regulates dimerization. Molecular and Cellular Biology 19 1002-1015.
21. Chen D, Washbrook E, Sarwar N, Bates G, Pace P, Thirunuvakkarasu V, Taylor J, Epstein R, Fuller-Pace F, Egly J et al. 2002 Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene 21 4921-4931. (doi:10.1038/sj.onc.1205420)
22. Cheskis BJ, Greger J, Cooch N, McNally C, McLarney S, Lam HS, Rutledge S, Mekonnen B, Hauze D, Nagpal S et al. 2008 MNAR plays an important role in ERa activation of Src/MAPK and PI3K/Akt signaling pathways. Steroids 73 901-905. (doi:10.1016/j.steroids.2007.12.028)
23. Clarke R, Liu M, Bouker K, Gu Z, Lee R, Zhu Y, Skaar T, Gomez B, O'Brien K, Wang Y et al. 2003 Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22 7316-7339. (doi:10.1038/sj.onc.1206937)
24. Cooper C, Liu G, Niu Y, Santos S, Murphy L & Watson P 2004 Intermittent hypoxia induces proteasome-dependent down-regulation of estrogen receptor α in human breast carcinoma. Clinical Cancer Research 10 8720-8727. (doi:10.1158/1078-0432.CCR-04-1235)
25. Creighton CJ, Hilger AM, Murthy S, Rae JM, Chinnaiyan AM & El-Ashry D 2006 Activation of mitogen-activated protein kinase in estrogen receptor α-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor a-negative human breast tumors. Cancer Research 66 3903-3911. (doi:10.1158/0008-5472.CAN-05-4363)
26. Cui Y, Zhang M, Pestell R, Curran EM, Welshons WV & Fuqua SA 2004 Phosphorylation of estrogen receptor α blocks its acetylation and regulates estrogen sensitivity. Cancer Research 64 9199-9208. (doi:10.1158/0008-5472.CAN-04-2126)
27. Dowsett M, Harper-Wynne C, Boeddinghaus I, Salter J, Hills M, Dixon M, Ebbs S, Gui G, Sacks N & Smith I 2001 HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Research 61 8452-8458.
28. Dutertre M & Smith C 2003 Ligand-independent interactions of p160/steroid receptor coactivators and CREB-binding protein (CBP) with estrogen receptor-alpha: regulation by phosphorylation sites in the A/B region depends on other receptor domains. Molecular Endocrinology 17 1296-1314. (doi:10.1210/me.2001-0316)
29. Elsberger B, Tan BA, Mitchell TJ, Brown SB, Mallon EA, Tovey SM, Cooke TG, Brunton VG & Edwards J 2009 Is expression or activation of Src kinase associated with cancer-specific survival in ER-, PR- and HER2-negative breast cancer patients? American Journal of Pathology 175 1389-1397. (doi:10.2353/ajpath.2009.090273)
30. Endoh H, Maruyama K, Masuhiro Y, Kobayashi Y, Goto M, Tai H, Yanagisawa J, Metzger D, Hashimoto S & Kato S 1999 Purification and identification of p68 RNA helicase acting as a transcriptional coactivator specific for the activation function 1 of human estrogen receptor α. Molecular and Cellular Biology 19 5363-5372.
31. Faus H & Haendler B 2006 Post-translational modifications of steroid receptors. Biomedicine and Pharmacotherapy 60 520-528. (doi:10.1016/j.biopha. 2006.07.082)
32. Fischle W, Wang Y & Allis CD 2003 Binary switches and modification cassettes in histone biology and beyond. Nature 425 475-479. (doi:10.1038/nature02017) (Pubitemid 37237036)
33. Font de Mora J & Brown M 2000 AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Molecular and Cellular Biology 20 5041-5047. (doi:10.1128/MCB.20.14.5041-5047.2000)
34. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS & Baum M 2008 Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncology 9 45-53. (doi:10.1016/S1470-2045(07)70385-6)
35. Gee J, Robertson J, Gutteridge E, Ellis I, Pinder S, Rubini M & Nicholson R 2005 Epidermal growth factor receptor/- HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocrine-Related Cancer 12 (Suppl 1) S99-S111. (doi:10.1677/erc.1. 01005)
36. Generali D, Buffa FM, Berruti A, Brizzi MP, Campo L, Bonardi S, Bersiga A, Allevi G, Milani M, Aguggini S et al. 2009 Phosphorylated ERα, HIF-1α, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. Journal of Clinical Oncology 27 227-234. (doi:10.1200/JCO.2007.13.7083)
37. Goss P, Ingle J, Martino S, Robert N, Muss H, Piccart M, Castiglione M, Tu D, Shepherd L, Pritchard K et al. 2003 A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. New England Journal of Medicine 349 1793-1802. (doi:10.1056/NEJMoa032312)
38. Grisouard J, Medunjanin S, Hermani A, Shukla A & Mayer D 2007 Glycogen synthase kinase-3 protects estrogen receptor α from proteasomal degradation and is required for full transcriptional activity of the receptor. Molecular Endocrinology 21 2427-2439. (doi:10.1210/me.2007-0129) (Pubitemid 47529356)
39. Gruvberger-Saal S, Bendahl P, Saal L, Laakso M, Hegardt C, Edén P, Peterson C, Malmström P, Isola J, Borg A et al. 2007 Estrogen receptor β expression is associated with tamoxifen response in ERα-negative breast carcinoma. Clinical Cancer Research 13 1987-1994. (doi:10.1158/1078-0432. CCR-06-1823) (Pubitemid 46649864)
40. Guo JP, Shu SK, Esposito NN, Coppola D, Koomen JM & Cheng JQ 2010 IKKepsilon phosphorylation of estrogen receptor alpha Ser-167 and contribution to tamoxifen resistance in breast cancer. Journal of Biological Chemistry 285 3676-3684. (doi:10.1074/jbc.M109.078212)
41. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK & Dowsett M 2005 Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. Journal of Clinical Oncology 23 2469-2476. (doi:10.1200/JCO.2005.01.172) (Pubitemid 47050837)
42. Hall J, Couse J & Korach K 2001 The multifaceted mechanisms of estradiol and estrogen receptor signaling. Journal of Biological Chemistry 276 36869-36872. (doi:10.1074/jbc.R100029200)
43. Hamilton-Burke W, Coleman L, Cummings M, Green CA, Holliday DL, Horgan K, Maraqa L, Peter MB, Pollock S, Shaaban AM et al. 2010 Phosphorylation of estrogen receptor β at serine 105 is associated with good prognosis in breast cancer. American Journal of Pathology 177 1079-1086. (doi:10.2353/ajpath. 2010.090886)
44. Harvey J, Clark G, Osborne C & Allred D 1999 Estrogen receptor status by immunohistochemistry is superior to the ligand binding assay for predicting response to adjuvant endocrine therapy in breast cancer. Journal of Clinical Oncology 17 1474-1481.
45. He X, Zheng Z, Song T, Wei C, Ma H, Ma Q, Zhang Y, Xu Y, Shi W, Ye Q et al. 2010 c-Abl regulates estrogen receptor alpha transcription activity through its stabilization by phosphorylation. Oncogene 29 2238-2251. (doi:10.1038/onc.2009.513)
46. Holm C, Kok M, Michalides R, Fles R, Koornstra RH, Wesseling J, Hauptmann M, Neefjes J, Peterse JL, Stal O et al. 2009 Phosphorylation of the oestrogen receptor α at serine 305 and prediction of tamoxifen resistance in breast cancer. Journal of Pathology 217 372-379. (doi:10.1002/path.2455)
47. Honma N, Horii R, Iwase T, Saji S, Younes M, Takubo K, Matsuura M, Ito Y, Akiyama F & Sakamoto G 2008 Clinical importance of estrogen receptor-β evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. Journal of Clinical Oncology 26 3727-3734. (doi:10.1200/JCO.2007.14.2968)
48. Jensen E & Jordan V 2003 The estrogen receptor: a model for molecular medicine. Clinical Cancer Research 9 1980-1989.
49. Jiang J, Sarwar N, Peston D, Kulinskaya E, Shousha S, Coombes R & Ali S 2007 Phosphorylation of estrogen receptor-α at Ser167 is indicative of longer disease-free and overall survival in breast cancer patients. Clinical Cancer Research 13 5769-5776. (doi:10.1158/1078-0432.CCR-07-0822)
50. Joel P, Smith J, Sturgill T, Fisher T, Blenis J & Lannigan DA 1998 pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167. Molecular and Cellular Biology 18 1978-1984.
51. Jordan V 2003 Is tamoxifen the Rosetta stone for breast cancer? Journal of the National Cancer Institute 95 338-340. (doi:10.1093/jnci/95.5.338)
52. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H et al. 1995 Activation of the estrogen receptor through phosphorylation by mitogen activated protein kinase. Science 270 1491-1494. (doi:10.1126/science.270.5241.1491)
53. Kirkegaard T, Witton C, McGlynn L, Tovey S, Dunne B, Lyon A & Bartlett J 2005 AKT activation predicts outcome in breast cancer patients treated with tamoxifen. Journal of Pathology 207 139-146. (doi:10.1002/path. 1829)
54. Knowlden J, Hutcheson I, Jones H, Madden T, Gee J, Harper M, Barrow D, Wakeling A & Nicholson R 2003 Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144 1032-1044. (doi:10.1210/en.2002-220620)
55. Kok M, Holm-Wigerup C, Hauptmann M, Michalides R, Stal O, Linn S & Landberg G 2009 Estrogen receptor-α phosphorylation at serine-118 and tamoxifen response in breast cancer. Journal of the National Cancer Institute 101 1725-1729. (doi:10.1093/jnci/djp412)
56. Kok M, Zwart W, Holm C, Fles R, Hauptmann M, Van't Veer LJ, Wessels LF, Neefjes J, Stal O, Linn SC et al. 2010 PKA-induced phosphorylation of ERalpha at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer. Breast Cancer Research and Treatment 125 1-12. (doi:10.1007/s10549-010-0798-y)
57. Lahn M, Kohler G, Sundell K, Su C, Li S, Paterson BM & Bumol TF 2004 Protein kinase C alpha expression in breast and ovarian cancer. Oncology 67 1-10. (doi:10.1159/000080279)
58. Landesman-Bollag E, Romieu-Mourez R, Song DH, Sonenshein GE, Cardiff RD & Seldin DC 2001 Protein kinase CK2 in mammary gland tumorigenesis. Oncogene 20 3247-3257. (doi:10.1038/sj.onc.1204411)
59. Lannigan D 2003 Estrogen receptor phosphorylation. Steroids 68 1-9. (doi:10.1016/S0039-128X(02)00110-1)
60. Lee H & BaiW2002 Regulation of estrogen receptor nuclear export by ligand-induced and p38-mediated receptor phosphorylation. Molecular and Cellular Biology 22 5835-5845. (doi:10.1128/MCB.22.16.5835-5845.2002)
61. Le Goff P, Montano MM, Schodin DJ & Katzenellenbogen BS 1994 Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. Journal of Biological Chemistry 269 4458-4466.
62. Leygue E, Dotzlaw H, Watson P & Murphy L 1998 Altered estrogen receptor α and β mRNAexpression during human breast tumorigenesis. Cancer Research 58 3197-3201. (Pubitemid 28371051)
63. Likhite VS, Stossi F, Kim K, Katzenellenbogen BS & Katzenellenbogen JA 2006 Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity. Molecular Endocrinology 20 3120-3132. (doi:10.1210/me.2006-0068)
64. Lopez-Tarruella S & Schiff R 2007 The dynamics of estrogen receptor status in breast cancer: re-shaping the paradigm. Clinical Cancer Research 13 6921-6925. (doi:10.1158/1078-0432.CCR-07-1399)
65. Masuhiro Y, Mezaki Y, Sakari M, Takeyama K, Yoshida T, Inoue K, Yanagisawa J, Hanazawa S, O'Malley B & Kato S 2005 Splicing potentiation by growth factor signals via estrogen receptor phosphorylation. PNAS 102 8126-8131. (doi:10.1073/pnas.0503197102)
66. McKenna N, Lanz R & O'Malley B 1999 Nuclear receptor coregulators: cellular and molecular biology. Endocrine Reviews 20 321-344. (doi:10.1210/er.20.3.321)
67. Medunjanin S, Hermani A, Servi BD, Grisouard J, Rincke G & Mayer D 2005 Glycogen synthase kinase-3 interacts with and phosphorylates estrogen receptor α and is involved in the regulation of receptor activity. Journal of Biological Chemistry 280 33006-33014. (doi:10.1074/jbc.M506758200)
68. Medunjanin S, Weinert S, Schmeisser A, Mayer D & Braun-Dullaeus RC 2010 Interaction of the double-strand break repair kinase DNA-PK and estrogen receptor-α. Molecular Biology of the Cell 21 1620-1628. (doi:10.1091/mbc.E09-08-0724)
69. Michalides R, Griekspoor A, Balkenende A, Verwoerd D, Janssen L, Jalink K, Floore A, Velds A, van't Veer L & Neefjes J 2004 Tamoxifen resistance by a conformational arrest of the estrogen receptor α after PKA activation in breast cancer. Cancer Cell 5 597-605. (doi:10.1016/j.ccr.2004.05.016)
70. Miller WR, Watson DM, Jack W, Chetty U & Elton RA 1993 Tumour cyclic AMP binding proteins: an independent prognostic factor for disease recurrence and survival in breast cancer. Breast Cancer Research and Treatment 26 89-94. (doi:10.1007/BF00682703)
71. Morena AM, Oshima CT, Gebrim LH, Egami MI, Silva MR, Segreto RA, Giannotti Filho O, Teixeira VP & Segreto HR 2004 Early nuclear alterations and immunohistochemical expression of Ki-67, Erb-B2, vascular endothelial growth factor (VEGF), transforming growth factor (TGF-beta1) and integrine-linked kinase (ILK) two days after tamoxifen in breast carcinoma. Neoplasma 51 481-486.
72. Murphy L & Watson P 2006 Is oestrogen receptor-β a predictor of endocrine therapy responsiveness in human breast cancer? Endocrine-Related Cancer 13 327-334. (doi:10.1677/erc.1.01141)
73. Murphy L, Cherlet T, Lewis A, Banu Y & Watson P 2003 New insights into estogen receptor function in human breast cancer. Annals of Medicine 35 614-631. (doi:10.1080/07853890310014579)
74. Murphy L, Niu Y, Snell L & Watson P 2004a Phospho-Serine-118 estrogen receptor-α expression in primary human breast tumors in vivo is associated with better disease outcome in women treated with tamoxifen. Clinical Cancer Research 10 5902-5906. (doi:10.1158/1078-0432.CCR-04-0191)
75. Murphy LC, Cherlet T, Adeyinka A, Niu Y, Snell L & Watson P 2004b Phospho-Serine-118 estrogen receptor-α detection in human breast tumors in vivo. Clinical Cancer Research 10 1354-1359. (doi:10.1158/1078-0432.CCR-03- 0112)
76. Murphy L, Weitsman G, Skliris G, Teh E, Li L, Peng B, Davie J, Ung K, Niu Y, Troup S et al. 2006 Potential role of estrogen receptor α phosphorylation at serine 118 in human breast cancer in vivo. Journal of Steroid Biochemistry and Molecular Biology 102 139-146. (doi:10.1016/j.jsbmb.2006.09. 021)
77. Murphy L, Skliris G, Rowan B, Al-Dhaheri M, Williams C, Penner C, Troup S, Begic S, Parisien M & Watson P 2009 The relevance of phosphorylated forms of estrogen receptor in human breast cancer in vivo. Journal of Steroid Biochemistry and Molecular Biology 114 90-95. (doi:10.1016/j.jsbmb.2009.01.017)
78. Nawaz Z & O'Malley B 2004 Urban renewal in the nucleus: is protein turnover by proteasomes absolutely required for nuclear receptor regulated transcription? Molecular Endocrinology 18 493-499. (doi:10.1210/me.2003-0388)
79. Osborne C 1998 Steroid hormone receptors in breast cancer management. Breast Cancer Research and Treatment 51 227-238. (doi:10.1023/A:1006132427948)
80. Osborne C, Elledge R & Fuqua S 1996 Estrogen receptors in breast cancer therapy. Science and Medicine 3 32-41.
81. Osborne C, Shou J, Massarweh S & Schiff R 2005 Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clinical Cancer Research 11 865s-870s.
82. Park K, Krishnan V, O'Malley B, Yamamoto Y & Gaynor R 2005 Formation of an IKKalpha-dependent transcription complex is required for estrogen receptor-mediated gene activation. Molecular Cell 18 71-82. (doi:10.1016/j. molcel.2005.03.006)
83. Pietras R, Arboleda J, Reese D, Wongvipat N, Pegram M, Ramos L, Gorman C, Parker M, Sliwkowski M & Slamon D 1995 HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone independent growth in human breast cancer cells. Oncogene 10 2435-2446.
84. Plaza-Menacho I, Morandi A, Robertson D, Pancholi S, Drury S, Dowsett M, Martin LA & Isacke CM 2010 Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance. Oncogene 29 4648-4657. (doi:10.1038/onc.2010.209)
85. Plotnikov A, Li Y, Tran TH, Tang W, Palazzo JP, Rui H & Fuchs SY 2008 Oncogene-mediated inhibition of glycogen synthase kinase 3 beta impairs degradation of prolactin receptor. Cancer Research 68 1354-1361. (doi:10.1158/0008-5472.CAN-07-6094)
86. Rayala SK, Talukder AH, Balasenthil S, Tharakan R, Barnes CJ, Wang RA, Aldaz CM, Khan S & Kumar R 2006 P21-activated kinase 1 regulation of estrogen receptor-alpha activation involves serine 305 activation linked with serine 118 phosphorylation. Cancer Research 66 1694-1701. (doi:10.1158/0008- 5472.CAN-05-2922)
87. Reid G, Hubner M, Metivier R, Brand H, Denger S, Manu D, Beaudouin J, Ellenberg J & Gannon F 2003 Cyclic, proteasome-mediated turnover of unliganded and liganded ERα on responsive promoters is an integral feature of estrogen signaling. Molecular Cell 11 695-707. (doi:10.1016/S1097-2765(03) 00090-X)
88. Robertson J 1996 Oestrogen receptor: a stable phenotype in breast cancer. British Journal of Cancer 73 5-12.
89. Robertson J 2002 Estrogen receptor downregulators: new antihormonal therapy for advanced breast cancer. Clinical Therapeutics 24 (Suppl A) A17-A30. (doi:10.1016/S0149-2918(02)85032-9)
90. Rogatsky I, Trowbridge J & Garabedian M 1999 Potentiation of human estrogen receptor α transcriptional activation through phosphorylation of serines 104 and 106 by the cyclin A-CDK2 complex. Journal of Biological Chemistry 274 22296-22302. (doi:10.1074/jbc.274.32.22296)
91. Sanchez M, Picard N, Sauve K & Tremblay A 2010 Challenging estrogen receptor β with phosphorylation. Trends in Endocrinology and Metabolism 21 104-110. (doi:10.1016/j.tem.2009.09.007)
92. Santen R, Song R, Zhang Z, Yue W & Kumar R 2004 Adaptive hypersensitivity to estrogen: mechanism for sequential responses to hormonal therapy in breast cancer. Clinical Cancer Research 10 337S-345S. (doi:10.1158/1078-0432.CCR-031207)
93. Santen RJ, Fan P, Zhang Z, Bao Y, Song RX & Yue W 2009 Estrogen signals via an extra-nuclear pathway involving IGF-1R and EGFR in tamoxifen-sensitive and -resistant breast cancer cells. Steroids 74 586-594. (doi:10.1016/j.steroids.2008.11.020)
94. Sarwar N, Kim J, Jiang J, Peston D, Sinnett H, Madden P, Gee J, Nicholson R, Lykkesfeldt A, Shousha S et al. 2006 Phosphorylation of ERα at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERα phosphorylation in breast cancer progression. Endocrine-Related Cancer 13 851-861. (doi:10.1677/erc.1.01123)
95. Schiff R, Massarweh S, Shou J, Bharwani L, Mohsin S & Osborne C 2004 Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clinical Cancer Research 10 331S-336S. (doi:10.1158/1078-0432.CCR-031212)
96. Shah Y & Rowan B 2005 The Src kinase pathway promotes tamoxifen agonist action in Ishikawa endometrial cells through phosphorylation-dependent stabilization of estrogen receptor (alpha) promoter interaction and elevated steroid receptor coactivator 1 activity. Molecular Endocrinology 19 732-748. (doi:10.1210/me.2004-0298)
97. Sims RJ III & Reinberg D 2008 Is there a code embedded in proteins that is based on post-translational modifications? Nature Reviews. Molecular Cell Biology 9 815-820. (doi:10.1038/nrm2502)
98. Skliris G, Leygue E, Curtis-Snell L, Watson P&Murphy L 2006 Expression of oestrogen receptor-β in oestrogen receptor-α negative human breast tumours. British Journal ofCancer 95 616-626. (doi:10.1038/sj.bjc. 6603295)
99. Skliris GP, Rowan BG, Al-Dhaheri M, Williams C, Troup S, Begic S, Parisien M, Watson PH & Murphy LC 2009 Immunohistochemical validation of multiple phospho-specific epitopes for estrogen receptor α (ERα) in tissue microarrays of ERα positive human breast carcinomas. Breast Cancer Research and Treatment 118 443-453. (doi:10.1007/s10549-008-0267-z)
100. Skliris GP, Nugent ZJ, Rowan BG, Penner CR, Watson PH & Murphy LC 2010 A phosphorylation code for oestrogen receptor-α predicts clinical outcome to endocrine therapy in breast cancer. Endocrine-Related Cancer 17 589-597. (doi:10.1677/ERC-10-0030)
101. Someya M, Sakata K, Matsumoto Y, Satoh M, Narimatsu H & Hareyama M 2007 Immunohistochemical analysis of Ku70/86 expression of breast cancer tissues. Oncology Reports 18 1483-1487.
102. Tharakan R, Lepont P, Singleton D, Kumar R & Khan S 2008 Phosphorylation of estrogen receptor alpha, serine residue 305 enhances activity. Molecular and Cellular Endocrinology 295 70-78. (doi:10.1016/j.mce. 2008.07.018)
103. Thomas RS, Sarwar N, Phoenix F, Coombes RC & Ali S 2008 Phosphorylation at serines 104 and 106 by Erk1/2 MAPK is important for estrogen receptor-alpha activity. Journal of Molecular Endocrinology 40 173-184. (doi:10.1677/JME-07-0165)
104. Valley C, Metivier R, Solodin N, Fowler A, Mashek M, Hill L & Alarid E 2005 Differential regulation of estrogen-inducible proteolysis and transcription by the estrogen receptor α N terminus. Molecular and Cellular Biology 25 5417-5428. (doi:10.1128/MCB.25.13.5417-5428.2005)
105. Wakasugi E, Kobayashi T, Tamaki Y, Nakano Y, Ito Y, Miyashiro I, Komoike Y, Miyazaki M, Takeda T, Monden T et al. 1997 Analysis of phosphorylation of pRB and its regulatory proteins in breast cancer. Journal of Clinical Pathology 50 407-412. (doi:10.1136/jcp.50.5.407)
106. Wang RA, Mazumdar A, Vadlamudi RK & Kumar R 2002 P21-activated kinase-1 phosphorylates and transactivates estrogen receptor-alpha and promotes hyperplasia in mammary epithelium. EMBO Journal 21 5437-5447. (doi:10.1093/emboj/cdf543)
107. Wang L, Yang X, Zhang X, Mihalic K, Fan Y, Xiao W, Howard O, Appella E, Maynard A & Farrar W 2004 Suppression of breast cancer by chemical modulation of vulnerable zinc fingers in estrogen receptor. Nature Medicine 10 40-47. (doi:10.1038/nm969)
108. Ward RD & Weigel NL 2009 Steroid receptor phosphorylation: assigning function to site-specific phosphorylation. Biofactors 35 528-536. (doi:10.1002/biof.66)
109. Weigel N & Moore N 2007 Steroid receptor phosphorylation: a key modulator of multiple receptor functions. Molecular Endocrinology 21 2311-2319. (doi:10.1210/me.2007-0101)
110. Weis K, Ekena K, Thomas J, Lazennec G & Katzenellenbogen B 1996 Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein. Molecular Endocrinology 10 1388-1398. (doi:10.1210/me.10.11.1388)
111. Weitsman G, Li L, Skliris G, Davie J, Ung K, Curtis-Snell L, Tomes L, Watson P & Murphy L 2006 Estrogen receptor-α phosphorylated at Serine 118 is present at the promoters of estrogen-regulated genes and is not altered due to Her2 over-expression. Cancer Research 66 10162-10170. (doi:10.1158/0008-5472.CAN-05-4111)
112. West NR & Watson PH 2010 S100A7 (psoriasin) is induced by the proinflammatory cytokines oncostatin-M and interleukin-6 in human breast cancer. Oncogene 29 2083-2092. (doi:10.1038/onc.2009.488)
113. Williams C, Smith CL & Rowan BG 2007 Identification of four novel phosphorylation sites in estrogen receptor α: impact on receptor-dependent gene expression and phosphorylation by protein kinase CK2. In The Endocrine Society's 89th Annual Meeting, pp P2-P258. Toronto, Canada.
114. Williams CC, Basu A, El-Gharbawy A, Carrier LM, Smith CL & Rowan BG 2009 Identification of four novel phosphorylation sites in estrogen receptor α: impact on receptor-dependent gene expression and phosphorylation by protein kinase CK2. BMC Biochemistry 10 36. (doi:10.1186/1471-2091-10-36)
115. Yamashita H, Nishio M, Kobayashi S, Ando Y, Sugiura H, Zhang Z, Hamaguchi M, Mita K, Fujii Y & Iwase H 2005 Phosphorylation of estrogen receptor α serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer. Breast Cancer Research 7 R753-R764. (doi:10.1186/bcr1285)
116. Yamashita H, Nishio M, Toyama T, Sugiura H, Kondo N, Kobayashi S, Fuji Y & Iwase H 2008 Low phosphorylation of estrogen receptor α (ERα) serine 118 and high phosphorylation of ERα serine 167 improve survival in ER-positive breast cancer. Endocrine-Related Cancer 15 755-763. (doi:10.1677/ERC-08-0078)
117. Yamashita H, Takahashi S, Ito Y, Yamashita T, Ando Y, Toyama T, Sugiura H, Yoshimoto N, Kobayashi S, Fujii Y et al. 2009 Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer. Cancer Science 100 2028-2033. (doi:10.1111/j.1349-7006.2009.01274.x)
118. Yamnik RL, Digilova A, Davis DC, Brodt ZN, Murphy CJ & Holz MK 2009 S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation. Journal of Biological Chemistry 284 6361-6369. (doi:10.1074/jbc.M807532200)
119. Yang C, Xin H, Kelley J, Spencer A, Brautigan D & Paschal B 2007 Ligand binding to the androgen receptor induces conformational changes that regulate phosphatase interactions. Molecular and Cellular Biology 27 3390-3404. (doi:10.1128/MCB.02411-06)
120. York B, Yu C, Sagen JV, Liu Z, Nikolai BC, Wu RC, Finegold M, Xu J & O'Malley BW 2010 Reprogramming the posttranslational code of SRC-3 confers a switch in mammalian systems biology. PNAS 107 11122-11127. (doi:10.1073/pnas. 1005262107)
121. Yudt M, Vorojeikina D, Zhong L, Kafar D, Sasson S, Gasiewicz T & Notides A 1999 Function of estrogen receptor tyrosine 537 in hormone binding, DNA binding, and transactivation. Biochemistry 38 14146-14156. (doi:10.1021/bi9911132)
122. Zhao H, Ou-Yang F, Chen IF, Hou MF, Yuan SS, Chang HL, Lee YC, Plattner R, Waltz SE, Ho SM et al. 2010 Enhanced resistance to tamoxifen by the c-ABL protooncogene in breast cancer. Neoplasia 12 214-223. (doi:10.1593/neo.91576)
123. Zoubir M, Mathieu M, Mazouni C, Liedtke C, Corley L, Geha S, Bouaziz J, Spielmann M, Drusche F, SymmansW et al. 2008 Modulation of ER phosphorylation on serine 118 by endocrine therapy: a new surrogate marker for efficacy. Annals of Oncology 19 1402-1406. (doi:10.1093/annonc/mdn151)